Find Lymphoma Clinical Trials near You | Oncology Clinical Research

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Main Line Health Center-Collegeville

from

Collegeville, PA

Baptist Memorial Hospital and Cancer Center-Golden Triangle

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Columbus, MS

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Beaumont Hospital-Dearborn

from

Dearborn, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Cancer Care Specialists of Illinois - Decatur

from

Decatur, IL

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Trinity Regional Medical Center

from

Fort Dodge, IA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Wheaton Franciscan Healthcare-Franklin

from

Franklin, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Palo Alto Medical Foundation-Fremont

from

Fremont, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Central Care Cancer Center - Garden City

from

Garden City, KS

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Tidelands Georgetown Memorial Hospital

from

Georgetown, SC

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Aurora Health Care Germantown Health Center

from

Germantown, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Central Care Cancer Center - Great Bend

from

Great Bend, KS

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Hawaii Cancer Care Inc-POB II

from

Honolulu, HI

Novant Health Presbyterian Medical Center Huntersville

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Huntersville, NC

Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Jonesboro, AR

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Northwell Health- Center for Advanced Medicine

from

Lake Success, NY

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Sechler Family Cancer Center

from

Lebanon, PA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Hope Cancer Clinic

from

Livonia, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Joseph London

from

London, KY

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Centra Lynchburg Hematology Oncology Clinic

from

Lynchburg, VA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Aurora Bay Area Medical Group-Marinette

from

Marinette, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Thompson Oncology Group-Maryville

from

Maryville, TN

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

UH Seidman Cancer Center at Landerbrook Health Center

from

Mayfield Heights, OH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Memorial Sloan Kettering Monmouth

from

Middletown, NJ

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Monticello Cancer Center

from

Monticello, MN

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Chancellor Center for Oncology

from

Newburgh, IN

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Ascension Providence Hospitals - Novi

from

Novi, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Nebraska Cancer Specialists - Omaha

from

Omaha, NE

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Alphonsus Medical Center-Ontario

from

Ontario, OR

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Hope Cancer Care of Nevada-Pahrump

from

Pahrump, NV

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Lake Huron Medical Center

from

Port Huron, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Beaufort Memorial Keyserling Cancer Center

from

Port Royal, SC

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Ascension Saint Mary's Hospital

from

Rhinelander, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Riverton Hospital

from

Riverton, UT

Great Lakes Cancer Management Specialists-Rochester Hills

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Rochester Hills, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Siteman Cancer Center at Christian Hospital

from

Saint Louis, MO

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Mercy Hospital South

from

Saint Louis, MO

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Kaiser San Rafael-Gallinas

from

San Rafael, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Essentia Health Sandstone

from

Sandstone, MN

UH Seidman Cancer Center at Firelands Regional Medical Center

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Sandusky, OH

MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Sanford, ME

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

HSHS Saint Nicholas Hospital

from

Sheboygan, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Marshfield Clinic Stevens Point Center

from

Stevens Point, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Ascension Saint Michael's Hospital

from

Stevens Point, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Novant Health Oncology Specialists-Davidson County

from

Thomasville, NC

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Macomb Hematology Oncology PC

from

Warren, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Joseph Warren Hospital

from

Warren, OH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

UPMC Susquehanna

from

Williamsport, PA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Abington Memorial Hospital-Asplundh Cancer Pavilion

from

Willow Grove, PA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Elizabeth Youngstown Hospital

from

Youngstown, OH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

IHA Hematology Oncology Consultants-Ann Arbor

from

Ypsilanti, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Genesis Healthcare System Cancer Care Center

from

Zanesville, OH

A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Status: Enrolling, Phase I
Updated: 12/31/1969

Memorial Sloan Kettering Bergen

from

Montvale, NJ

A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Status: Enrolling, Phase I
Updated: 12/31/1969

Washington University; Wash Uni. Sch. Of Med

from

Saint Louis, MO

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

Status: Enrolling, Phase I
Updated: 12/31/1969

from

Houston, TX

Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Status: Enrolling, Phase II
Updated: 12/31/1969

Memorial Sloan Kettering Bergen

from

Montvale, NJ

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Status: Enrolling, Phase II
Updated: 12/31/1969

Border Medical Oncology Research Unit

from

Albury,

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Status: Enrolling, Phase II
Updated: 12/31/1969

University Cancer & Blood Center, LLC; Research

from

Athens, GA

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Status: Enrolling, Phase II
Updated: 12/31/1969

Wheaton Franciscan Cancer Care-All Saints

from

Franklin, WI

Immunology / Infectious Diseases, Oncology Clinical Trial

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Status: Enrolling, Phase II
Updated: 12/31/1969

Midwestern Regional Medical Center

from

Zion, IL

Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL

Status: Enrolling, Phase I
Updated: 12/31/1969

Inova Melanoma and Skin Cancer Center / Inova Schar Cancer Institute

from

Fairfax, VA

Non-Hodgkin's Disease Clinical Trial

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

Status: Enrolling, Phase I, II
Updated: 12/31/1969

BC Cancer Agency - Vancouver Centre

from

Vancouver,

Immunology / Infectious Diseases, Oncology Clinical Trial

Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms

Status: Enrolling, Phase I
Updated: 12/31/1969

Zuckerberg San Francisco General Hospital

from

San Francisco, CA

Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial

Project: Every Child for Younger Patients With Cancer

Status: Enrolling, Phase
Updated: 12/31/1969

Kaiser Permanente Downey Medical Center

from

Downey, CA

Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial

Project: Every Child for Younger Patients With Cancer

Status: Enrolling, Phase
Updated: 12/31/1969

University of Florida Health Science Center ?? Gainesville

from

Gainesville, FL

Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial

Project: Every Child for Younger Patients With Cancer

Status: Enrolling, Phase
Updated: 12/31/1969

Saint Vincent Hospital Cancer Center Green Bay

from

Green Bay, WI

Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial

Project: Every Child for Younger Patients With Cancer

Status: Enrolling, Phase
Updated: 12/31/1969

Alliance for Childhood Diseases/Cure 4 the Kids Foundation

from

Las Vegas, NV

Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial

Project: Every Child for Younger Patients With Cancer

Status: Enrolling, Phase
Updated: 12/31/1969

NYU Winthrop Hospital

from

Mineola, NY

Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial

Project: Every Child for Younger Patients With Cancer

Status: Enrolling, Phase
Updated: 12/31/1969

Mount Sinai Hosp

from

New York, NY

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Allentown, PA

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Long Beach, CA

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Maywood, IL

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

New York, NY

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

Status: Enrolling, Phase III
Updated: 12/31/1969

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma Clinical Trial

from

Salt Lake City, UT

QUILT-3.002: ALT-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Status: Enrolling, Phase I, II
Updated: 12/31/1969

Washington University School of Medicine Oncology

from

Saint Louis, MO

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Status: Enrolling, Phase I, II
Updated: 12/31/1969

from

Philadelphia, PA

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Status: Enrolling, Phase I, II
Updated: 12/31/1969

from

Saint Louis, MO

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

Status: Enrolling, Phase III
Updated: 12/31/1969

Local Institution

from

New Lambton Heights,

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

Status: Enrolling, Phase III
Updated: 12/31/1969

All Children's Hospital Specialty Physicians

from

Saint Petersburg, FL

Follicular Lymphoma Clinical Trial

Dose Optimization Study of Idelalisib in Follicular Lymphoma

Status: Enrolling, Phase III
Updated: 12/31/1969

St Vincent's Public Hospital Sydney

from

Darlinghurst,

Cutaneous T-Cell Lymphoma Clinical Trial

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

Status: Enrolling, Phase III
Updated: 12/31/1969

University of Arizona

from

Phoenix, AZ

Hodgkin's Lymphoma Clinical Trial

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)

Status: Enrolling, Phase II
Updated: 3/3/2016

from

Albany, NY

Hodgkin's Lymphoma Clinical Trial

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)

Status: Enrolling, Phase II
Updated: 3/3/2016

from

Birmingham, AL

Hodgkin's Lymphoma Clinical Trial

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)

Status: Enrolling, Phase II
Updated: 3/3/2016

from

Colorado Springs, CO

A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

Status: Enrolling, Phase I
Updated: 4/11/2016

from

Goshen, IN

Status: Enrolling, Phase I
Updated: 4/11/2016

from

Harvey, IL

Status: Enrolling, Phase I
Updated: 4/11/2016

from

Tucson, AZ

A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers

Status: Enrolling, Phase I, II
Updated: 12/31/1969

Research Facility

from

Cleveland, OH

Non-Hodgkin's Lymphoma Clinical Trial

A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

Status: Enrolling, Phase I
Updated: 12/31/1969

Memorial Healthcare System

from

Pembroke, FL

Non-Hodgkin's Lymphoma Clinical Trial

A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

Status: Enrolling, Phase I
Updated: 12/31/1969

Royal North Shore Hospital; Haematology Department

from

St. Leonards,

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Status: Enrolling, Phase III
Updated: 12/31/1969

New York Cancer and Blood Specialists

from

East Setauket, NY

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Status: Enrolling, Phase III
Updated: 12/31/1969

Memorial Sloan Kettering Cancer Center-Monmouth

from

Middletown, NJ

Oncology, Psychiatry / Psychology Clinical Trial

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Status: Enrolling, Phase III
Updated: 12/31/1969

Hematology Oncology Center of Nyack Hospital

from

Nyack, NY

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

Status: Enrolling
Updated: 12/31/1969

Memorial Sloan Kettering Cancer Center ( Site 1229)

from

Harrison, NY

Oncology, Psychiatry / Psychology Clinical Trial

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

Status: Enrolling
Updated: 12/31/1969

Memorial Sloan Kettering Bergen

from

Montvale, NJ

University of Michigan Medical School CS Mott Children's Hospital

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Ann Arbor, MI

Sepulveda Ambulatory Care Center, Veterans Affairs Greater

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Status: Enrolling, Phase III
Updated: 12/31/1969

Queen Fabiola Children'S University Hospital Huderf

from

Brussel,

Adenoma Clinical Trial

Comparing the ADR With Air Insufflation, Water Immersion and Water Exchange During Two-endoscopist Colonoscopy

Status: Enrolling
Updated: 4/8/2016

from

North Hills, CA